BEGIN:VCALENDAR VERSION:2.0 PRODID:-//CERN//INDICO//EN BEGIN:VEVENT SUMMARY:Key talk: Idea of theranostics in nuclear medicine. Where we are? DTSTART;VALUE=DATE-TIME:20220711T081000Z DTEND;VALUE=DATE-TIME:20220711T083500Z DTSTAMP;VALUE=DATE-TIME:20260720T192722Z UID:indico-contribution-38-579@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Leszek Krolicki\; Medical University of Warsaw\, Pol and ()\nTheranostics is a relatively new field of medicine\, although its roots go back at least 70 years. This principle implies that treatment sho uld be based on well-defined medical/biological goals defined by imaging m ethods.\nOver the last decade\, there has been rapid progress in this area . In recent years\, the number of publications on theranostic techniques h as reached around 1\,000/year. Theranostics covers various areas: radioiso tope-based therapy\, bioimage guided radiotherapy\, optical imaging\, lase r ablation and surgery or nanotherapy.\n• Radiotheranostics is perhaps t he most advanced clinical application of theranostics\, with many advances and emerging opportunities. In these procedures\, indications for radiois otope therapy are based directly on the results of scintigraphic images: s cintigraphy indicates whether a given radiopharmaceutical accumulates in t he appropriate amount in the tumor\; a therapeutic radiopharmaceutical is used only when the scintigraphy indicates a sufficiently large accumulatio n of the diagnostic form of the radiopharmaceutical. Therefore\, pairs of radioisotopes are sought - emitting gamma radiation (for diagnostics) and emitting beta or alpha radiation (for therapeutic purposes). Examples incl ude 123I (for diagnosis) and 131I (for treatment) in malignant or benign t hyroid diseases. The second direction of the development of radiotheranost ics is the use of known theranostic radiopharmaceuticals in the diagnosis and treatment of other diseases. An example is the use of somatostatin ana logues labelled with 177Lu in the treatment of pheochromocytoma\, breast c ancer\, small-cell lung cancer or meningioma. 177Lu labelled PSMA is adapt ed for treatment of thyroid\, hepatocellular or renal cancer. The examinat ions are conducted on the use of various radioisotopes depending on the ty pe and severity of the disease. The search for new therapeutic targets is also underway. The current results indicate that new therapeutic targets m ay turn out to be CXCR-4\, FAPI\, gastrin-releasing peptide receptor\, int egrin αVβ3 or αVβ5 receptors\, CD38\, CD45.\nThe next direction in the development of theranostics is the use of tandem therapies. The combinati on of radioisotope treatment and chemo-/immunotherapy seems to be more eff ective. An important achievement in recent years is also the possibility o f characterizing the tumor microenvironment: activity of immune cells and fibroblasts\, extracellular matrix or angiogenesis. This information is he lpful (or even critical) in selecting the appropriate treatment for patien ts.\nToday\, radiotheranostics constitutes a new view on therapeutic proce dures\, and nuclear medicine is currently the best tool for its developmen t.\n\nhttps://indico.koza.if.uj.edu.pl/event/7/contributions/579/ LOCATION:Collegium Maius URL:https://indico.koza.if.uj.edu.pl/event/7/contributions/579/ END:VEVENT BEGIN:VEVENT SUMMARY:Key talk: Clinical and Technical Consideration for Fast TOF PET DTSTART;VALUE=DATE-TIME:20220711T074500Z DTEND;VALUE=DATE-TIME:20220711T081000Z DTSTAMP;VALUE=DATE-TIME:20260720T192722Z UID:indico-contribution-38-578@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Georges El Fakhri\, Gordon Center\, Massachusetts Ge neral Hospital\, Harvard Medical School\, USA ()\nG. El Fakhria\, J. Álam o i\, J. Barberái\, J.M. Benllochi\, G. Borghib\, R. Dolenecc\,d\, J. M. Fernández-Tenlladoe\, D. Gascóne\, S. Gómezf\,e\, A. Golab\, K. Grogga\ , D. Gubermane\, S. Korparg\,d\, P. Križanc\,d\, S. Majewskih\, R. Manera e\, T. Marina\, A. Mariscal-Castillae\, J. Mauricioe\, S. Merzib\, C. More ra i\, M. Oreharc\, G. Pavóni M. Pennab\, R. Pestotnikd\, G. Razdevšekc \, H. Sabetha\, A. Seljakd\, A. Studenc\,d\n\naGordon Center for Medical I maging and Harvard Medical School\, Boston\, MA 02114\, United States\,\nb Fondazione Bruno Kessler\, 38123 Povo TN\, Italy\,\ncFaculty of Mathematic s and Physics\, University of Ljubljana\, Ljubljana\, Slovenia\,\ndJožef Stefan Institute\, Ljubljana\, Slovenia\,\neDept. Física Quàntica i Astr ofísica\, Institut de Ciències Del Cosmos (ICCUB)\, University of Barcel ona (IEEC-UB)\, Barcelona\, Spain\,\nfSerra Húnter Fellow\, Polytechnic U niversity of Catalonia (UPC)\, Barcelona\, Spain\,\ngFaculty of Chemistry and Chemical Engineering\, University of Maribor\, Maribor\, Slovenia\,\nh University of California Davis\, Davis\, CA 9b616\, United States of Ameri ca\, \niOncovision\, Valencia\, Spain\n\nThe paradigm shift in medicine fr om treatment of acute and/or advanced disease to very early diagnosis and even prevention in cancer\, neurodegenerative as well as cardiac fields\, puts more stringent requirements on PET imaging both in terms of sensitivi ty as well as specificity. Likewise\, recent developments in Targeted Rad ionuclide Therapy (TRT) where theragnostic pairs are used to tailor a pers onalized treatment in terms of dose using PET initial imaging and subseque nt alpha or beta emitting radionuclides have introduced a clear and urgent need for more widespread and accurate PET imaging. Standard clinical scan ners are sub-optimal both in terms of cost that\, limit widespread use\, a s well as performance. Standard clinical PET scanners use sets of tightly arranged rings of detector modules\, consisting of scintillation crystals optically coupled to light sensors with readout electronics. They cover on ly a limited solid angle\, and just a small few percent fraction of the po sitron decays is registered. Novel long axial PET scanners with axial fiel d of view offer a very attractive solution to many of the challenges detai led above\, especially in terms of increased sensitivity and enabling fast dosimetry and biodistribution for pharmacokinetic studies\, that will pav e the way to personalized TRT. However\, these scanners pose significant challenges both financially and logistically. In this talk we present a jo int effort between JSI-Ljubljana\, FBK-Trento\, Univ-Barcelona\, Oncovisio n and MGH-Harvard-Boston to address these challenges using fast coincidenc e timing resolution. On the front electronics\, our challenge is to develo p a low-noise\, high-dynamic-range ASIC with a time resolution of 20 ps or better\, and with on-chip time-to-digital converter (TDC). To achieve sub -100 ps CTR we intend to explore 2.5 D integration with the photo-sensor. Recent advances in Time-of-flight (TOF) PET technology afford a rare oppor tunity to improve signal-to-noise-ratio (SNR) without increasing the cost associated with axial coverage by resorting to very sparse angular coverag e of the patient and long axial field coverage (>1m). This would yield aff ordable long axial PET scanners with increased sensitivity that can enable full body pharmacokinetics and pharmacodynamics.\n\nhttps://indico.koza.i f.uj.edu.pl/event/7/contributions/578/ LOCATION:Collegium Maius URL:https://indico.koza.if.uj.edu.pl/event/7/contributions/578/ END:VEVENT BEGIN:VEVENT SUMMARY:Opening talk: Potential Applications of Total Body PET Imaging wit h Emphasis on CV\, MSK and Malignant Disorders DTSTART;VALUE=DATE-TIME:20220711T070000Z DTEND;VALUE=DATE-TIME:20220711T074500Z DTSTAMP;VALUE=DATE-TIME:20260720T192722Z UID:indico-contribution-38-577@indico.koza.if.uj.edu.pl DESCRIPTION:Speakers: Abass Alavi\; University of Pennsylvania\, USA ()\nT he introduction of X-Ray by Roentgen in 1895 started a major revolution in medicine and still continues to have an impact on its current practice on a daily basis. However\, no major\, physics-based invention was initiated until the 1960s when David Kuhl at the University of Pennsylvania (Penn) introduced the concept of tomography as we know today. He and his colleagu es were first to design an instrument that allowed radiation-based imaging of brain tumors by a technique that was called “emission tomography” at the time. The invention of Computed Tomography (CT) by Hounsfield in 19 71 added a major dimension to modern imaging armamentarium. While prototyp e CT imaging was somewhat complicated and limited in scope\, over the past 5 decades\, this very powerful imaging modality has matured significantly and is nowadays the workhorse of clinical practice of medicine. The intro duction of the concept of MRI in 1970s by Lauterbur added a major dimensio n to medical imaging and its role in complicated diseases and disorders.\n \nInitial applications of emission tomography were primarily focused on as sessing blood-brain barrier abnormalities by conventional radiotracers. Ho wever\, the significant superiority of contrast enhanced CT over emission tomography propelled investigators at Penn to introduce the concept of ass essing brain glucose metabolism by radiolabeled deoxyglucose. Efforts at P enn soon led to synthesizing 18F-Fluorodeoxyglucose (FDG) and the first hu man studies were performed in August 1976. The success of this effort was a major stimulus to mobilizing forces for practical applications of positr on emitting radiopharmaceuticals for both research and clinical purposes. Investigators at Washington University\, led by Michael Ter-Pegossian\, de signed and built prototype positron emission tomography (PET) instruments that further enhanced the role of the modality in many settings. Over the years\, significant advances have been made in designing CT\, MRI\, and PE T imaging which has improved practical applications of such instruments. I n 2000\, the first hybrid PET/CT instrument was introduced by investigator s at the University of Pittsburgh\, and this allowed combining molecular i mages acquired by PET with those of CT. During the past 10 years\, PET/MRI instruments have further enhanced our ability to combine the advantages o f these two powerful modalities as a single powerful unit.\n\nDuring the p ast several years\, investigators at University of California\, Davis and United Imaging in Shanghai have designed and built total body PET/CT instr uments for simultaneous imaging of the entire body with a single acquisiti on. Similar approaches have been adopted by investigates at Penn\, the Uni versity of Kraków\, and Siemens which is further enhancing the role of th is approach worldwide.\n\nOver the past few decades\, molecular imaging wi th PET has made a major impact in many domains in medicine. While initial interests were focused on brain imaging because of the\n\nlimitations of a vailable instruments during the early years of PET technology\, the introd uction of body imaging has expanded interests into imaging various maligna ncies\, cardiovascular disorders\, and many infectious/inflammatory diseas es. The application of PET to the day-to-day practice of medicine has subs tantially improved patient care in many disciplines including neurology\, oncology\, orthopedics\, and other disorders of mankind. These approaches have substantially influenced management of patients and avoiding unnecess ary and costly procedures. Because of the success of FDG\, many new tracer s have been introduced over the years that have shown great promise in ass essment of both benign and malignant abnormalities. The ability for succes sful quantification by PET has also made a major contribution to the succe ss of this modality. During the past few decades\, great interest of globa l disease assessment by the medical imaging for many systemic disorders ha s become a reality employing conventional PET instruments with a limited f ield of view. This approach provides a single number that represents disea se activity throughout the body and has significant implications for optim al management of the affected population. Therefore\, the ability to image the entire body with total body PET instruments combined with such quanti tative capabilities will have far reaching impact in the future. In convul sion\, the revolution that has evolved over the past 5 decades in medical imaging is unparalleled in any discipline in medicine and this will lead t o substantially improved patient care in the future worldwide.\n\nhttps:// indico.koza.if.uj.edu.pl/event/7/contributions/577/ LOCATION:Collegium Maius URL:https://indico.koza.if.uj.edu.pl/event/7/contributions/577/ END:VEVENT END:VCALENDAR